Out-licensing

These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE).

Summary

A class of drugs for imaging of Alzheimer's disease progression and response to therapy. These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). In addition to use as a highly efficient imaging model, there is the potential for therapeutic benefit due to the fact that the compounds inhibit BChE. An additional therapeutic use may stem from the fact that BChE is also expressed in ovarian cancer making the compounds useful in this area as well.

Market Value

Alzheimer's disease is the most common cause of dementia, afflicting 24 million people worldwide. Despite of advances in medicine, currently there is no efficient imaging and treatment systems for Alzheimer's Disease. The technology presented is developed on growing demand for Alzheimer's Disease diagnostic and treatment tools among aging U.S. and Europe population.

Features & Benefits

• Early detection and evaluation of AD and its progression
• Highly sensitive imaging
• Efficient inhibition of AD progression
• Additional application of BChE related diseases

Early Stage

US Patent Application Filed:

     12/188,641

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with University of Nebraska Medical Center.